CME/CE: Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis
This course discusses the research that highlighted the significant costs associated with MASH,...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 169 results for 'MASH'
CME/CE: Study Identifies Most Accurate Noninvasive Model for Diagnosing MASH
This course discusses that compared three noninvasive methods of detecting MASH and patients at...
Read MoreMRI Biomarkers Identify Histologic Improvement in MASH
Identifying suitable biomarkers that can be used to replace liver biopsy or to determine patients who would benefit from one is garnering interest in both the clinical management of MASH and drug development. Research published...
Read More
MASH With Significant Fibrosis Increases CV Risk, Regardless of Diabetes Status
Liver fibrosis in MASH is linked with elevated risk for cardiovascular events, according to an analysis of NHANES study data.
Read More
Novel Test Improves Detection of Advanced Fibrosis in MASH by More Than 10%
A two-step approach combining the SAFE and MR-MASH scores performed well in indicating patients with at-risk MASH.
Read More
AI Tool May Improve Reliability of MASH Clinical Trials
An AI measurement tool delivered accurate and reproducible scoring measures in MASH, including fibrosis and progression-free survival.
Read MoreAI Tool May Improve Reliability of MASH Clinical Trials
AI-based measurement tool for scoring metabolic dysfunction-associated steatohepatitis (MASH) histology (AIM-MASH) predicted MASH Clinical Research Network necroinflammation grades and fibrosis stages that aligned with expert...
Read MorePatients Report Most Bothersome MASH Symptoms
Understanding patient experiences with MASH symptoms and their effect on day to-day life can enhance patient-clinician discussions and facilitate patient-centered treatment and disease management, according to a real-world,...
Read MoreOptimizing Guideline-Based MASH Management: A Synthesis of International Recommendations
Metabolic dysfunctionassociated steatotic liver disease (MASLD) is often asymptomatic, and when symptoms do present, they are nonspecific and rarely trigger alarm bells. The primary care setting is often the first line of...
Read MoreAdvertisement
Novel MRI Score Validated for MASH Diagnosis & Management
The prevalence of MASH is increasing worldwide. A model created at the Cleveland Clinic Lerner College of Medicine projects that the number of Metabolic dysfunction associated steatotic liver disease (MASLD) cases is going to...
Read MoreTargeted Efforts Needed for Patients With MASH & MetS
MASH poses significant risks as it can lead to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. The prevalence of MASH closely mirrors that of metabolic syndrome (MetS), which exacer bates the risk of advanced...
Read More
Certain Liver Histologic Features Predict Long-Term MASH Progression and Outcomes
Liver histologic features play a crucial role in forecasting long-term clinical outcomes in patients with MASLD and its inflammatory subtype, MASH.
Read More
AI Improves MASH Diagnosis
Researchers developed machine learning algorithms that used clinical data and blood parameters to predict metabolic dysfunction-associated steatohepatitis.
Read More
#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 (HealthDay News) — For patients with metabolic...
Read MorePrevalence and Risk Factors of Anemia in the MASHAD Cohort Study.
Anemia is a serious public health problem which may be associated with cardiovascular diseases (CVDs) and brain damage. This survey aims to determine the prevalence of anemia and its association with demographic and biochemical...
Read MoreDistribution of group a circulating in Mashhad, Iran.
Group A (RVA) is the most important causative agent of acute diarrheal disease in pediatrics 5 years and below. This study aimed to determine the distribution of circulating RVA in Mashhad, Iran to develop health improvement...
Read More![[Preliminary exploration of modified side overlap with fundoplication by Yamashita (mSOFY) anastomosis technique in laparoscopic proximal gastrectomy].](https://cdn.physiciansweekly.com/wp-content/uploads/2023/08/Digestive-system-gastroenterology-sketch-scaled.jpg)
[Preliminary exploration of modified side overlap with fundoplication by Yamashita (mSOFY) anastomosis technique in laparoscopic proximal gastrectomy].
To discuss the feasibility and safety of modified side overlap with fundoplication by Yamashita...
Read More
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics...
Read More
The relationship between genetic variants associated with primary ovarian insufficiency and lipid profile in women recruited from MASHAD cohort study.
Primary Ovarian Insufficiency (POI) is defined by the occurrence of menopause before the age of...
Read More